Conversion surgery for gastric cancer patients: A review

Table 2 Overall survival and median survival time

Reference	Years	OS (rate)			MST (mo)
		CHT	CHT + surgery		CHT	CHT + surgery
			R1/R2	R0		R1/R2	R0
Nakajima et al[73], 1997	2/3-yr				4.7	6.5
	5-yr			55.6
Yano et al[74], 20022	2/3-yr
	5-yr
Satoh et al[75], 2012	2/3-yr		43	751			19.2
	5-yr
Kanda et al[76], 2012	2/3-yr		0	45.9			29
	5-yr			34.4
Han et al[77], 2014	2/3-yr			41.4		7.8	22.9
	5-yr
Kim et al[78], 2014	2/3-yr	0	0	50	8	18	37
	5-yr
Fukuchi et al[79], 2015	2/3-yr				14	30	62
	5-yr	1	15	49
Kinoshita et al[80], 2015	2/3-yr	0	16	63.5	9.6	29.9
	5-yr
Sato et al[81], 2017	2/3-yr	18.7			15.7	21.7	47.9
	5-yr	0	0	48.6
Einama et al[82], 2017	2/3-yr						29
	5-yr
Mieno et al[83], 2017	2/3-yr	56.9		73.1		56.1
	5-yr
Yamaguchi et al[84], 2017	2/3-yr				11.3	21.2	41.3
	5-yr
Morgagni et al[85], 2018	2/3 yr	0		39.4	14		383
	5 yr

¹R0 in only pre-Cy1 patients;

²No data are specified but a P value < 0.0003 is shown between resected and not-resected 5-years OS rate;

³Patients who had cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had an MST of 50 mo. OS: Overall survival; MST: Median survival time; CHT: Chemotherapy.